Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells

BCR signaling pathway inhibitors such as Syk inhibitors[1][1]–[3][2] have shown promise in CLL, a mature B cell cancer where the BCR pathway is constitutively active.[4][3] However, sustained BCR signaling can lead to anergy and apoptosis in a process including IgM downregulation, reduced